Inhibiting Eph kinase activity may not be “Eph”ective for cancer treatment
- 17 November 2014
- journal article
- review article
- Published by Taylor & Francis in Growth Factors
- Vol. 32 (6) , 207-213
Abstract
Several Eph receptor tyrosine kinases (RTKs) are commonly over-expressed in epithelial and mesenchymal cancers and are recognized as promising therapeutic targets. Although normal interaction between Eph receptors and their ephrin ligands stimulates kinase activity and is generally tumor suppressive, significant Eph over-expression allows activation of ligand- and/or kinase-independent signaling pathways that promote oncogenesis. Single-agent kinase inhibitors are widely used to target RTK-driven tumors but acquired and de novo resistance to such agents is a major limitation to effective clinical use. Accumulating evidence suggests that Ephs can be inhibited by “leaky” or low-specificity kinase inhibitors targeted at other RTKs. Such off-target effects may therefore inadvertently promote ligand- and/or kinase-independent oncogenic Eph signaling, thereby providing a new mechanism by which resistance to the RTK inhibitors can emerge. We propose that combining specific, non-leaky kinase inhibitors with tumor-suppressive stimulators of Eph signaling may provide more effective treatment options for overcoming treatment-induced resistance and clinical failure.Keywords
This publication has 82 references indexed in Scilit:
- Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapiesEndocrine-Related Cancer, 2014
- Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLCJournal of Clinical Investigation, 2014
- Therapeutic targeting of EPH receptors and their ligandsNature Reviews Drug Discovery, 2013
- The EphA2 Receptor Drives Self-Renewal and Tumorigenicity in Stem-like Tumor-Propagating Cells from Human GlioblastomasCancer Cell, 2012
- Regulation and misregulation of Eph/ephrin expressionCell Adhesion & Migration, 2012
- Eph/ephrin signaling: networksGenes & Development, 2008
- The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signalingJournal of Clinical Investigation, 2008
- Characterization of a novel Eph receptor tyrosine kinase, EphA10, expressed in testisBiochimica et Biophysica Acta (BBA) - General Subjects, 2005
- Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivoOncogene, 2002
- Tyrosine Phosphorylation of Transmembrane Ligands for Eph ReceptorsScience, 1997